ProCE Banner Activity

How Newly Approved CPX-351 Will Change AML Treatment

Clinical Thought
CPX-351 is beginning to replace traditional 3+7 chemotherapy for secondary or high-risk AML. Learn what you need to know to use it effectively in the clinic.

Released: September 28, 2017

Expiration: September 27, 2018

No longer available for credit.

Share

Faculty

Jeffrey E. Lancet

Jeffrey E. Lancet, MD

Senior Member & Professor
Chair,
 Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by educational grants from

Astellas Text

Daiichi Sankyo, Inc.

Jazz Pharmaceuticals Inc

Pfizer, Inc.

Faculty Disclosure

Primary Author

Jeffrey E. Lancet, MD

Senior Member & Professor
Chair,
 Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Jeffrey E. Lancet, MD, has disclosed that he has received consulting fees from Bio-Path Holdings, BioSight, Celgene, Erytech, and Janssen and funds for research support from BioSight and Celgene.